Viking Therapeutics Competitors

Viking Therapeutics (NASDAQ:VKTX) and Morphic (NASDAQ:MORF) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, profitability, institutional ownership, valuation, dividends, analyst recommendations and risk.

Valuation and Earnings

This table compares Viking Therapeutics and Morphic's top-line revenue, earnings per share (EPS) and valuation.

Viking Therapeutics has higher earnings, but lower revenue than Morphic. Morphic is trading at a lower price-to-earnings ratio than Viking Therapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Viking Therapeutics has a beta of 2.02, indicating that its share price is 102% more volatile than the S&P 500. Comparatively, Morphic has a beta of 1.01, indicating that its share price is 1% more volatile than the S&P 500.

Institutional and Insider Ownership

54.1% of Viking Therapeutics shares are held by institutional investors. Comparatively, 61.5% of Morphic shares are held by institutional investors. 3.7% of Viking Therapeutics shares are held by company insiders. Comparatively, 39.5% of Morphic shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Viking Therapeutics and Morphic's net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of recent ratings for Viking Therapeutics and Morphic, as reported by MarketBeat.com.

Viking Therapeutics currently has a consensus target price of $16.4444, indicating a potential upside of 180.14%. Morphic has a consensus target price of $63.3333, indicating a potential upside of 14.98%. Given Viking Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Viking Therapeutics is more favorable than Morphic.

Summary

Viking Therapeutics beats Morphic on 10 of the 13 factors compared between the two stocks.

Viking Therapeutics (NASDAQ:VKTX) and Pandion Therapeutics (NASDAQ:PAND) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, profitability, institutional ownership and valuation.

Insider & Institutional Ownership

54.1% of Viking Therapeutics shares are owned by institutional investors. Comparatively, 35.7% of Pandion Therapeutics shares are owned by institutional investors. 3.7% of Viking Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Viking Therapeutics and Pandion Therapeutics' net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Viking Therapeutics and Pandion Therapeutics' revenue, earnings per share and valuation.

Pandion Therapeutics has higher revenue and earnings than Viking Therapeutics.

Analyst Ratings

This is a breakdown of recent recommendations for Viking Therapeutics and Pandion Therapeutics, as reported by MarketBeat.

Viking Therapeutics currently has a consensus target price of $16.4444, indicating a potential upside of 180.14%. Pandion Therapeutics has a consensus target price of $44.25, indicating a potential downside of 26.31%. Given Viking Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Viking Therapeutics is more favorable than Pandion Therapeutics.

Summary

Viking Therapeutics beats Pandion Therapeutics on 6 of the 10 factors compared between the two stocks.

Five Prime Therapeutics (NASDAQ:FPRX) and Viking Therapeutics (NASDAQ:VKTX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability and analyst recommendations.

Insider & Institutional Ownership

67.3% of Five Prime Therapeutics shares are held by institutional investors. Comparatively, 54.1% of Viking Therapeutics shares are held by institutional investors. 6.4% of Five Prime Therapeutics shares are held by company insiders. Comparatively, 3.7% of Viking Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Five Prime Therapeutics and Viking Therapeutics, as reported by MarketBeat.

Five Prime Therapeutics currently has a consensus target price of $30.7143, indicating a potential downside of 19.17%. Viking Therapeutics has a consensus target price of $16.4444, indicating a potential upside of 180.14%. Given Viking Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Viking Therapeutics is more favorable than Five Prime Therapeutics.

Profitability

This table compares Five Prime Therapeutics and Viking Therapeutics' net margins, return on equity and return on assets.

Volatility & Risk

Five Prime Therapeutics has a beta of 4.4, suggesting that its stock price is 340% more volatile than the S&P 500. Comparatively, Viking Therapeutics has a beta of 2.02, suggesting that its stock price is 102% more volatile than the S&P 500.

Valuation & Earnings

This table compares Five Prime Therapeutics and Viking Therapeutics' gross revenue, earnings per share and valuation.

Viking Therapeutics has lower revenue, but higher earnings than Five Prime Therapeutics. Viking Therapeutics is trading at a lower price-to-earnings ratio than Five Prime Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Viking Therapeutics beats Five Prime Therapeutics on 10 of the 14 factors compared between the two stocks.

Cytokinetics (NASDAQ:CYTK) and Viking Therapeutics (NASDAQ:VKTX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, profitability, earnings, dividends and institutional ownership.

Institutional & Insider Ownership

97.1% of Cytokinetics shares are owned by institutional investors. Comparatively, 54.1% of Viking Therapeutics shares are owned by institutional investors. 6.4% of Cytokinetics shares are owned by company insiders. Comparatively, 3.7% of Viking Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Cytokinetics and Viking Therapeutics' revenue, earnings per share and valuation.

Viking Therapeutics has lower revenue, but higher earnings than Cytokinetics. Viking Therapeutics is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Cytokinetics and Viking Therapeutics' net margins, return on equity and return on assets.

Risk & Volatility

Cytokinetics has a beta of 1.45, suggesting that its share price is 45% more volatile than the S&P 500. Comparatively, Viking Therapeutics has a beta of 2.02, suggesting that its share price is 102% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and target prices for Cytokinetics and Viking Therapeutics, as provided by MarketBeat.com.

Cytokinetics presently has a consensus price target of $33.6364, suggesting a potential upside of 36.18%. Viking Therapeutics has a consensus price target of $16.4444, suggesting a potential upside of 180.14%. Given Viking Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Viking Therapeutics is more favorable than Cytokinetics.

Summary

Viking Therapeutics beats Cytokinetics on 10 of the 14 factors compared between the two stocks.

Viking Therapeutics (NASDAQ:VKTX) and Amneal Pharmaceuticals (NYSE:AMRX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, valuation, profitability, institutional ownership, analyst recommendations, risk and dividends.

Profitability

This table compares Viking Therapeutics and Amneal Pharmaceuticals' net margins, return on equity and return on assets.

Risk and Volatility

Viking Therapeutics has a beta of 2.02, indicating that its stock price is 102% more volatile than the S&P 500. Comparatively, Amneal Pharmaceuticals has a beta of 1.27, indicating that its stock price is 27% more volatile than the S&P 500.

Earnings & Valuation

This table compares Viking Therapeutics and Amneal Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Viking Therapeutics has higher earnings, but lower revenue than Amneal Pharmaceuticals. Viking Therapeutics is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

54.1% of Viking Therapeutics shares are held by institutional investors. Comparatively, 33.5% of Amneal Pharmaceuticals shares are held by institutional investors. 3.7% of Viking Therapeutics shares are held by insiders. Comparatively, 26.3% of Amneal Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Viking Therapeutics and Amneal Pharmaceuticals, as reported by MarketBeat.

Viking Therapeutics presently has a consensus target price of $16.4444, indicating a potential upside of 180.14%. Amneal Pharmaceuticals has a consensus target price of $7.00, indicating a potential upside of 18.85%. Given Viking Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Viking Therapeutics is more favorable than Amneal Pharmaceuticals.

Ironwood Pharmaceuticals (NASDAQ:IRWD) and Viking Therapeutics (NASDAQ:VKTX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, risk, analyst recommendations, valuation, institutional ownership and dividends.

Valuation and Earnings

This table compares Ironwood Pharmaceuticals and Viking Therapeutics' top-line revenue, earnings per share and valuation.

Ironwood Pharmaceuticals has higher revenue and earnings than Viking Therapeutics. Viking Therapeutics is trading at a lower price-to-earnings ratio than Ironwood Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings for Ironwood Pharmaceuticals and Viking Therapeutics, as reported by MarketBeat.com.

Ironwood Pharmaceuticals presently has a consensus price target of $11.40, indicating a potential upside of 7.45%. Viking Therapeutics has a consensus price target of $16.4444, indicating a potential upside of 180.14%. Given Viking Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Viking Therapeutics is more favorable than Ironwood Pharmaceuticals.

Insider & Institutional Ownership

54.1% of Viking Therapeutics shares are owned by institutional investors. 2.4% of Ironwood Pharmaceuticals shares are owned by insiders. Comparatively, 3.7% of Viking Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Ironwood Pharmaceuticals and Viking Therapeutics' net margins, return on equity and return on assets.

Risk and Volatility

Ironwood Pharmaceuticals has a beta of 1.46, indicating that its stock price is 46% more volatile than the S&P 500. Comparatively, Viking Therapeutics has a beta of 2.02, indicating that its stock price is 102% more volatile than the S&P 500.

Summary

Viking Therapeutics beats Ironwood Pharmaceuticals on 8 of the 14 factors compared between the two stocks.